Afina Retinal Imaging
Alzheimer's Disease Diagnosis
Validation/DevelopmentActive
Key Facts
Indication
Alzheimer's Disease Diagnosis
Phase
Validation/Development
Status
Active
Company
About NeuroVision Imaging
NeuroVision Imaging is a private, venture-backed company addressing critical gaps in the neurology care pathway through a dual-platform strategy. Its core technology, the Afina Retinal Imaging platform, uses AI to detect amyloid signatures in the retina as a non-invasive biomarker for Alzheimer's and Cerebral Amyloid Angiopathy (CAA). Concurrently, the company's BrainHealth.net telehealth platform offers scalable diagnostic and managed services, including patient triage, preventative neurology coaching, genetic testing, and clinical trial matching, aiming to improve access and outcomes in cognitive healthcare.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| iRS-AD | BetaSense | Research/Development |
| Aβ1-40/Aβ1-42/Tau IMR Reagents | MagQu | Commercial |
| Alzheimer's Biomarker | Aelan Cell Technologies | Test Stage |
| Oligomer Diagnostic Biomarkers | Abyssinia Biologics | Preclinical/Research |
| ABtest-Service | Araclon Biotech | Commercial |
| AlzTEST® | Neuron Biopharma | Not Specified |